论文部分内容阅读
目的对比观察非离子型造影剂欧乃派克和离子型造影剂复方泛影葡胺在CT增强扫描中的副反应，讨论其机理及临床应用价值。材料与方法：观察受检病人1178例，欧乃派克组262例，60％复方泛影葡胺组916例，造影剂量60～100ml。结果：欧乃派克发生副反应2例（0．76％）；复方泛影葡胺发生到反应52例（5．68％）（P＜0．001）。结论：非离子型造影剂由于其良好的理化特性，副反应明显低于离子型造影剂，因此在CT扫描中，特别是高危人群应尽量使用非离子型造影剂。
OBJECTIVE To compare and observe the adverse reaction of nonionic contrast agent Omnipaque and ionic contrast agent compound meglumine diatrizoate in CT enhanced scanning and to discuss its mechanism and clinical application value. MATERIALS AND METHODS: A total of 1178 patients were examined, 262 patients in Omnipaeg group, 916 patients in 60% compound diatrizoate group and 60-100 ml contrast agent. RESULTS: Two cases (0.76%) of Omnipaque had side effects and the other 52 cases (5.68%) responded to dipyridamole (P <0.001). Conclusion: Because of its good physical and chemical properties, non-ionic contrast agents have significantly lower side effects than ionic contrast agents. Therefore, non-ionic contrast agents should be used as much as possible in CT scans, especially in high-risk groups.